clinical trial · NCT06417554
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·recruiting·n = 80
Advanced Solid TumorsSHR-A2102SHR-A2102 ; Adebrelimab injectionSHR-A2102 + Disitamab Vedotin For Injection
brief summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
started
May 27, 2024
primary completion
Dec 31, 2031
completion
Dec 31, 2031
last updated
Aug 24, 2026
official title
A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol